Nyxoah (NYXH) - Total Assets
Based on the latest financial reports, Nyxoah (NYXH) holds total assets worth €93.60 Million EUR (≈ $109.43 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Nyxoah service its debt to assess how comfortably operating cash covers total debt obligations.
Nyxoah - Total Assets Trend (2017–2024)
This chart illustrates how Nyxoah's total assets have evolved over time, based on quarterly financial data. See net assets of Nyxoah for net asset value and shareholders' equity analysis.
Nyxoah - Asset Composition Analysis
Current Asset Composition (December 2024)
Nyxoah's total assets of €93.60 Million consist of 61.9% current assets and 38.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 21.6% |
| Accounts Receivable | €3.38 Million | 2.1% |
| Inventory | €4.72 Million | 3.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €50.38 Million | 31.8% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Nyxoah's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Nyxoah worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nyxoah's current assets represent 61.9% of total assets in 2024, a decrease from 95.9% in 2017.
- Cash Position: Cash and equivalents constituted 21.6% of total assets in 2024, down from 90.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 31.8% of total assets.
Nyxoah Competitors by Total Assets
Key competitors of Nyxoah based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
BMC Medical Co. Ltd. A
SHE:301367
|
China | CN¥3.38 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SD Biosensor Inc
KO:137310
|
Korea | ₩3.98 Trillion |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
Dentium
KO:145720
|
Korea | ₩932.79 Billion |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK
|
Indonesia | Rp980.33 Billion |
|
Nissan
TA:NISA
|
Israel | ILA654.44 Million |
Nyxoah - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.70 | 5.28 | 14.70 |
| Quick Ratio | 1.41 | 4.95 | 14.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €14.59 Million | €67.76 Million | €87.71 Million |
Nyxoah - Advanced Valuation Insights
This section examines the relationship between Nyxoah's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.34 |
| Latest Market Cap to Assets Ratio | 0.39 |
| Asset Growth Rate (YoY) | 27.6% |
| Total Assets | €158.41 Million |
| Market Capitalization | $62.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nyxoah's assets below their book value (0.39x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Nyxoah's assets grew by 27.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nyxoah (2017–2024)
The table below shows the annual total assets of Nyxoah from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €158.41 Million ≈ $185.19 Million |
+27.59% |
| 2023-12-31 | €124.16 Million ≈ $145.15 Million |
-15.00% |
| 2022-12-31 | €146.07 Million ≈ $170.77 Million |
-14.49% |
| 2021-12-31 | €170.83 Million ≈ $199.72 Million |
+49.75% |
| 2020-12-31 | €114.08 Million ≈ $133.37 Million |
+650.77% |
| 2019-12-31 | €15.20 Million ≈ $17.76 Million |
-15.48% |
| 2018-12-31 | €17.98 Million ≈ $21.02 Million |
+61.32% |
| 2017-12-31 | €11.14 Million ≈ $13.03 Million |
-- |
About Nyxoah
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgi… Read more